Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.
Y-HEP Health Center | Jonathan Lax Health Center
The following clinical trials are ongoing at the Lax Center and currently enrolling patients:
WINCORE
Description: A longitudinal, observational study evaluating immune outcomes of COVID-19 vaccination in at risk populations
VAMOS
Trial Number: TH9507-CTR-1030
Description: The Visceral Adiposity and Measurements Observational Study
A Randomized, Open-Label Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir for HIV Treatment
Trial Number: GS-US-563-6041
Description: A Phase 2 Randomized, Open‑Label, Active‑Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV
Studies of the Immunopathogenesis of Chronic and Emerging Viral Infections
Description: Sponsored by The Wistar Institute
The following clinical trials are ongoing at the Lax Center but are NOT enrolling new patients:
DEFINE
Trial Number: TMC114FD2HTX4004
Description: Symtuza (D/C/F/TAF) Single Tablet Regimen (STR) Evaluated as an STR in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain
The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:
Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir (LEN) for HIV Pre-Exposure Prophylaxis (PrEP)
Trial Number: GS-US-528-9023
Description: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection
Acceptability of Long-Acting Injectable Lenacapavir (LEN) Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for HIV Pre-Exposure Prophylaxis (PrEP): Qualitative Insights Into Social and Behavioral Contexts
Trial Number: GS-US-528-6364
Description: A Qualitative Study for participants already enrolled in GS-US-528-9023 to examine Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People
PennE
Description: Supporting PrEP Initiation and Mental Health Screening in Community Care Settings with Automated, Proactive Text-Messaging
For more information on any of the clinical trials listed, please contact the Research Department at 215-344-1631.